BRÈVE

sur GENFIT (EPA:GNFT)

GENFIT to Present Latest ACLF Research at EASL Congress™ 2024

Graphique de l'évolution du cours de l'action GENFIT (EPA:GNFT).

GENFIT, a late-stage biopharmaceutical company focused on rare liver diseases, will present its latest research on Acute on-Chronic Liver Failure (ACLF) at the EASL Congress™ 2024. A key event will be co-hosted with the European Foundation for the Study of Chronic Liver Failure (EF CLIF) to kick off a research collaboration.

Experts including Professor Richard Moreau from EF CLIF, Pascal Prigent, CEO of GENFIT, and Dean Hum, GENFIT's Chief Scientific Officer, will be speaking. EF CLIF and GENFIT will work with the Global Liver Institute and European Liver Patients' Association in this initiative.

GENFIT's presence at the Congress will feature two significant posters. The first suggests that GENFIT’s VS-01 captures metabolites associated with ACLF, while the second shows Nitazoxanide’s potential to protect against stress-induced cell death in preclinical models of ACLF.

Additional activities include the UNVEIL-IT® Investigator Meeting and an ELPA educational training event, emphasizing GENFIT’s commitment to patient advocacy and ongoing research in ACLF.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de GENFIT